Aligos Therapeutics, INC 8-K filings

Aligos Therapeutics reported Q2 2026 results, highlighting a $25M upfront payment for pevifoscorvir sodium licensing and a $3M milestone for ALG-170675, alongside a reduced net loss but continued R&D investment.

Aligos Therapeutics stockholders approved an amendment to the 2020 Employee Stock Purchase Plan and re-elected two directors at the 2026 Annual Meeting.

Aligos Therapeutics has entered into a licensing agreement with Xiamen Amoytop Biotech for the development and commercialization of its Hepatitis B drug in China.

Aligos Therapeutics announced positive interim results from its Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic Hepatitis B, alongside FDA Fast Track Designation.

Aligos Therapeutics reports significant pipeline progress and a substantial reduction in net loss for Q4 and full year 2025.

Aligos Therapeutics announced third quarter 2025 financial results and pipeline updates, highlighting progress in its Phase 2 HBV study and promising preclinical data for ALG-055009.

Aligos Therapeutics announced significant progress in its lead chronic hepatitis B program, ALG-000184, entering Phase 2, alongside reporting a net loss of $15.9 million for the second quarter of 2025.

Aligos Therapeutics, Inc. announced that its stockholders approved significant increases in authorized common stock and the company's incentive award plan, providing greater flexibility for future capital management and employee compensation.

Aligos Therapeutics announces progress in clinical trials for HBV and MASH treatments, along with a strengthened financial position following a recent capital raise.

Aligos Therapeutics announced recent business progress, including a $105 million private placement, and financial results for the fourth quarter and full year 2024, highlighting advancements in their pipeline programs.

Aligos Therapeutics secures $105 million in a private placement to advance its ALG-000184 Phase 2 clinical study and extend its cash runway into the second half of 2026.

Aligos Therapeutics has appointed Lesley Ann Calhoun as Chief Operating Officer, effective immediately, while she continues to serve as Chief Financial Officer.

Aligos Therapeutics reported positive topline data for its MASH treatment and provided a financial update for the third quarter of 2024.

Aligos Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Aligos Therapeutics enacted a 1-for-25 reverse stock split of its common stock, effective August 19, 2024, to comply with Nasdaq's minimum bid price requirement.

Aligos Therapeutics has increased its board size to seven members, appointing Heather Preston and Margarita Chavez as new directors effective August 7, 2024.

Aligos Therapeutics announced positive clinical trial updates and its second quarter 2024 financial results, highlighting progress in its drug development programs.

Aligos Therapeutics' stockholders approved an increase in authorized shares and an amendment to the 2020 Incentive Award Plan at their annual meeting on June 27, 2024.

Aligos Therapeutics received a notification from Nasdaq for not meeting the minimum requirement of three independent directors on its Audit Committee following a recent resignation.

Aligos Therapeutics has reported the resignation of a board member, leading to non-compliance with Nasdaq listing rules regarding the composition of its Audit Committee.

Aligos Therapeutics announces the resignation of its Chief Medical Officer, Matthew McClure, effective May 9, 2024.

Aligos Therapeutics announced its first quarter 2024 financial results and provided updates on its clinical programs, including the initiation of a Phase 2a study and positive data from ongoing trials.

Aligos Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and a recent $92 million private placement.

Aligos Therapeutics successfully concluded its stock option exchange program, resulting in the cancellation of 3,880,332 options and the issuance of 1,906,153 replacement options.

Aligos Therapeutics is launching a voluntary option exchange program for eligible employees and directors to address underwater stock options due to market conditions.